11:06 AM EDT, 07/02/2024 (MT Newswires) -- London's High Court on Tuesday handed down a mixed ruling in connection with the COVID-19 vaccine patent legal battle between Moderna ( MRNA ) on one side and Pfizer ( PFE ) and BioNTech (BNTX) on the other.

The court ruled that a Moderna ( MRNA ) patent, EP565, was "invalid," while another patent, EP949, was "valid" and was infringed by Pfizer ( PFE ) and BioNTech.

"We are pleased that the UK High Court recognized the innovation of Moderna ( MRNA ) scientists by confirming the validity and infringement of the EP'949 Patent," Moderna ( MRNA ) said in a statement emailed to MT Newswires. "We disagree with some other aspects of the decisions and will consider addressing those issues on appeal."

BioNTech told MT Newswires in an emailed statement that the company and its partner Pfizer ( PFE ) will seek to appeal the decision for EP949, saying that neither of the patents was valid.

"Irrespective of the outcome of this legal matter, we will continue to manufacture and supply the Pfizer-BioNTech COVID-19 vaccine in line with our agreements and established supply schedules," BioNTech said.

Pfizer ( PFE ) didn't immediately respond to a request for comment from MT Newswires.

Price: 115.14, Change: -0.81, Percent Change: -0.70